Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
24/06/2021
0:00
13:01
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
Mais episódios de "JAMA Oncology Author Interviews"
Não percas um episódio de “JAMA Oncology Author Interviews” e subscrevê-lo na aplicação GetPodcast.